Matilda Biotech (002932.SZ) announced its 2023 annual results forecast. It is expected to be a listed company stock for the whole year...
According to the Zhitong Finance App, Matilda Biotech (002932.SZ) released its 2023 annual results forecast. Net profit attributable to shareholders of listed companies is expected to be 55 million yuan to 75 million yuan for the whole year, down 98.22% to 98.69% from the previous year.
The main reasons are: (1) the company's operating income declined, leading to a sharp decline in the company's net profit; (2) it was difficult for end customers to repay, credit risk increased, and bad debt provisions were made for some high-risk customers; (3) after continuous expansion of production capacity over the past three years, the amount of the company's fixed assets was large, which led to higher depreciation expenses.